Feasibility and efficacy of 8 week Glecaprevir/Pibrentasvir to treat incarcerated viraemic HCV patients: A case‐control study
- 23 November 2020
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 41 (2) , 271-275
Abstract
Inmates have higher HCV prevalence than general population, representing a fundamental step towards HCV eradication. Our aim was to compare eight‐weeks glecaprevir/pibrentasvir treatment in a case‐control study between incarcerated and free patients. Eleven Italian prisons and six outpatient clinics were involved. Patients were matched for sex, risk factors, METAVIR grade, HIV and HBV co‐infections. 131 incarcerated (Group A) and 131 free patients (Group B) were included. Mean age was 43.0±9.6 years and 42.8±9.9 in Group A and B, respectively (p=0.74). SVR rates were 96.2% and 99.2% in Group A and Group B respectively (p=0.21). Five drop‐outs occurred in Group A, one in Group B. Incarceration, being PWIDs and OST were not associated to SVR reductions (CI 95%). In conclusion, imprisonment does not influence unplanned interruptions or SVR rates when receiving short‐term therapies. Short schedules with pangenotypic regimens could be a good approach to hard‐to‐reach populations, such as incarcerated patients.Keywords
This publication has 16 references indexed in Scilit:
- Treatment with direct-acting antivirals in a multicenter cohort of HCV-infected inmates in ItalyInternational Journal of Drug Policy, 2018
- EASL Recommendations on Treatment of Hepatitis C 2018Journal of Hepatology, 2018
- High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosisJournal of Hepatology, 2018
- Demonstration of Near-Elimination of Hepatitis C Virus Among a Prison Population: The Lotus Glen Correctional Centre Hepatitis C Treatment ProjectClinical Infectious Diseases, 2018
- Direct-acting antiviral agents for HCV infection affecting people who inject drugsNature Reviews Gastroenterology & Hepatology, 2017
- Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling studyThe Lancet Gastroenterology & Hepatology, 2017
- A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapyJournal of Viral Hepatitis, 2016
- Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conferenceJournal of Viral Hepatitis, 2016
- Prevalence and epidemiological correlates and treatment outcome of HCV infection in an Italian prison settingBMC Public Health, 2013
- Incidence and prevalence of hepatitis C in prisons and other closed settings: Results of a systematic review and meta-analysisHepatology, 2013